Sickle Cell Disease Clinical Trial
Official title:
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Verified date | June 2020 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study's goal is to determine the frequency and severity of acute graft versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, to determine the time to neutrophil and platelet engraftment, to determine the time to immune reconstitution (including normalization of T, B and natural killer (NK) cell repertoire and Immunoglobulin G production), and to establish the incidence of infectious complications including bacterial, viral, fungal and atypical mycobacterial and other infections following CD34+ selection in children, adolescents and young adults receiving an allogeneic peripheral blood stem cell transplant from a family member or unrelated adult donor for a non-malignant disease.
Status | Active, not recruiting |
Enrollment | 37 |
Est. completion date | January 2030 |
Est. primary completion date | January 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 40 Years |
Eligibility |
Inclusion Criteria: - General Eligibility (All Patients) - Patient must be < or = 40 years of age. Patients with sickle cell anemia must be at least 2 years of age. - Patient or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human Services. - Approval for the use of this treatment protocol by the individual institution's Human Rights Committee must be obtained, in accordance with the institutional assurance policies of the U. S. Department of Health and Human Services. - Human leukocyte antigen (HLA) typing will be performed by high-resolution molecular DNA typing for HLA Class I A, B, and C and HLA Class II DRB1 and DQB1 alleles. - Unrelated donor: An 8/10, 9/10 or 10/10 matched unrelated adult donor (MUD) will be required for study entry. - Related Donor: A 5/10, 6/10, 7/10, 8/10, 9/10 or 10/10 matched (or partially matched) family donor will be required for study entry. - Non-malignant Disorders per protocol. - Hemoglobinopathies per protocol. - Requirement for CD34+ stem cell selection for a second infusion of stem cells following an allogeneic stem cell transplant from a related or unrelated adult donor. - Additional eligibility for patients with non-malignant disorders receiving myeloablative conditioning - Adequate renal function as determined by the institutional normal range. - Adequate liver function per protocol. - Adequate cardiac function defined by radionucleotide angiogram or echocardiogram. - Adequate pulmonary function by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry >94% on room air. - Additional eligibility for patients with non-malignant disorders receiving reduced intensity conditioning - Adequate renal function as determined by the institutional normal range. - Adequate liver function per protocol. - Adequate cardiac function per protocol. - Adequate pulmonary function per protocol. Exclusion Criteria: - Patients with documented uncontrolled infection at the time of study entry are not eligible. - Pregnancy/Breast-Feeding Females who are pregnant or breast feeding at the time of study entry are not eligible. -- The following additional exclusion criteria for patients with sickle cell anemia the following exclusion criteria also apply - Patients with bridging fibrosis or cirrhosis of the liver. - Uncontrolled bacterial, viral or fungal infection in the past month. - Seropositivity for HIV. - Patients who have received prior hematocrit (HCT) within three months of enrollment for reduced intensity regimen and within six months for myeloablative regimen/reduced toxicity regimens. |
Country | Name | City | State |
---|---|---|---|
United States | Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Diane George |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of acute graft versus host disease (GVHD) | Determine the incidence and severity of acute GVHD. | 100 days | |
Secondary | Incidence of primary graft failure | Quantify the incidence of primary and secondary graft failure. | 1 year | |
Secondary | Survival Rate | To assess event free survival and overall survival | 5 years | |
Secondary | Time to neutrophil and platelet engraftment | To determine the time to neutrophil and platelet engraftment | 1 year | |
Secondary | Time to immune reconstitution | To determine the time to immune reconstitution (including normalization of T, B and NK cell repertoire and Immunoglobulin G production) | 2 years | |
Secondary | Incidence of infectious complications | To establish the incidence of infectious complications including bacterial, viral, fungal and atypical mycobacterial and other infections | 2 years | |
Secondary | Incidence of secondary graft failure | Quantify the incidence of primary and secondary graft failure. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 | |
Completed |
NCT02567682 -
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
|
Phase 1 |